Spots Global Cancer Trial Database for A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Official Title: A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Study ID: NCT05451849
Conditions
Study Description
Brief Summary: TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, San Francisco, San Francisco, California, United States
University of Miami, Miami, Florida, United States
National Cancer Institute, Bethesda, Maryland, United States
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
Montefiore Einstein Cancer Center, Bronx, New York, United States
University of Oklahoma, Oklahoma City, Oklahoma, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
